Conmed (CNMD) Tops Q4 EPS by 4c, Beats on Revenues; Offers FY18 EPS Outlook Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
CONMED (CNMD) PT Raised to $54 at Piper Jaffray
February 1, 2018 6:41 AM ESTPiper Jaffray raised its price target on CONMED (NASDAQ: CNMD) to $54.00 (from $46.00) while maintaining a Neutral rating.
... MoreCONMED (CNMD) PT Raised to $71 at Needham & Company
February 1, 2018 6:22 AM ESTNeedham & Company raised its price target on CONMED (NASDAQ: CNMD) to $71.00 (from $58.00) while maintaining a Buy rating.
Analyst Mike Matson commented, "CNMD's 4Q17 revenue and EPS beat consensus and management guided to above-consensus 2018 revenue and EPS. Its revenue growth improved to... More
